Pharmacokinetic concerns related to the AIDS Clinical Trial Group (ACTG) A5262 trial

AIDS

Volumn 26, Issue 3, 2012, Pages 398-400

  Gervasoni, Cristina ^a   Cattaneo, Dario ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; RALTEGRAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS LOAD;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; RITONAVIR; SULFONAMIDES;

EID: 84855386789     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e9d9e     Document Type: Letter

References (9)

1. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011; 25:2113-2122.
2. Cattaneo D, Ripamonti D, Gervasoni C, Landonio S, Meraviglia P, Baldelli S, et al. Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. J Clin Pharmacol 2011 [Epub ahead of print].
3. Burger D, Colbers EPH, van Luin M, Koopmans PP. AUC0-3 h of raltegravir is correlated to AUC0-12 h: a novel approach for therapeutic drug monitoring of raltegravir [abstract 41]. In: 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2010; Sorrento, Italy.
4. Grobler JA, McKenna PM, Ly S. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitor [abstract O-10]. In: 10th International Workshop on Clinical Pharmacology of HIV Therapy; 15-17 April 2009; Amsterdam, the Netherlands.
5. McSharry J, Weng Q, Zager K, Soldani K, Kulawy R, Drusano G. Pharmacodynamics of raltegravir, an HIV integrase inhibitor in an in vitro hollow fiber infection model system [abstract A-960]. In: ICAAC/IDSA; October 2008; Washington, District of Columbia, USA.
6. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 51:1376-1402.
7. Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res 2011; 63:249-253.
8. Boffito M, Moyle M, Hill A, Sekar V, Lefebvre E, De Pauw M. The pharmacokinetic profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 h [abstract P-31]. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2008; New Orleans, Louisiana, USA.
9. Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Influence of raltegravir on the pharmacokinetics of darunavir in HIV-1-infected patients. Pharmacol Res 2011 [Epub ahead of print].